Micardis leads the charge for Boehringer Ingelheim in Japan
This article was originally published in Scrip
Prescription sales at Nippon Boehringer Ingelheim (NBI) in Japan rose by around 6% to ¥173.8 billion ($1.85 billion) at reimbursement prices in calendar 2009, driven by global strategic products including Micardis (telmisartan) and Spiriva (tiotropium).
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.